The drug combines an RNAi payload with an agent designed to stimulate a patient's immune system against their tumors.
Title: Nucleic Acid Microparticles for Pulmonary Delivery Patent Number: 8,808,747 Filed: April 17, 2008
NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.
Gradalis has promoted Phillip Maples as executive vice president and chief technical officer.
Following the close of Dicerna Pharmaceuticals Series C round of financing last week, the RNAi therapeutics space has seen a dramatic increase in investor interest, with privately held companies in the field pulling in more than $100 million thus far in 2013.
Jul 25, 2013
May 16, 2013
Jan 3, 2013
Gradalis Raises $24M in Series B
Nov 8, 2012
Oct 11, 2012
Nov 4, 2010
Mar 11, 2010
Feb 19, 2009
Feb 5, 2009